NCT00058552View on ClinicalTrials.gov

A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2004

Conditions
Ovarian Cancer
Interventions
DRUG

Pertuzumab (rhuMAb 2C4)

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT00058552 - A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer | Biotech Hunter | Biotech Hunter